Headlines about AxoGen (NASDAQ:AXGN) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AxoGen earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 45.8603854700364 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news articles that may have effected Accern’s rankings:

AxoGen (NASDAQ AXGN) traded up $0.50 during mid-day trading on Friday, hitting $24.90. The company had a trading volume of 414,682 shares, compared to its average volume of 225,187. The company has a debt-to-equity ratio of 1.93, a current ratio of 3.55 and a quick ratio of 2.95. The stock has a market cap of $831.89, a P/E ratio of -62.25 and a beta of 0.12. AxoGen has a 52-week low of $9.55 and a 52-week high of $31.70.

AXGN has been the topic of a number of research analyst reports. Jefferies Group initiated coverage on AxoGen in a research report on Thursday, November 30th. They issued a “buy” rating and a $35.00 target price on the stock. Cantor Fitzgerald set a $37.00 target price on AxoGen and gave the company a “buy” rating in a research report on Monday, January 8th. BidaskClub downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 11th. Leerink Swann lifted their target price on AxoGen from $23.00 to $26.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Finally, Wedbush restated a “buy” rating and issued a $27.00 target price (up previously from $22.00) on shares of AxoGen in a research report on Tuesday, November 21st. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. AxoGen has an average rating of “Buy” and an average price target of $29.33.

In related news, Director Guido J. Neels sold 1,150,000 shares of the business’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $19.74, for a total value of $22,701,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jamie Mark Grooms sold 21,290 shares of the business’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $26.22, for a total value of $558,223.80. The disclosure for this sale can be found here. Insiders sold a total of 1,293,990 shares of company stock worth $26,494,898 in the last quarter. Company insiders own 9.33% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “AxoGen (AXGN) Given Media Sentiment Score of 0.11” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://theolympiareport.com/2018/02/10/axogen-axgn-given-media-sentiment-score-of-0-11.html.

About AxoGen

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Insider Buying and Selling by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.